Header Logo

Connection

Prudence Ive to Antiretroviral Therapy, Highly Active

This is a "connection" page, showing publications Prudence Ive has written about Antiretroviral Therapy, Highly Active.
  1. Brief Report: Assessing the Association Between Changing NRTIs When Initiating Second-Line ART and Treatment Outcomes. J Acquir Immune Defic Syndr. 2018 04 01; 77(4):413-416.
    View in: PubMed
    Score: 0,125
  2. Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa. Trop Med Int Health. 2016 09; 21(9):1131-7.
    View in: PubMed
    Score: 0,111
  3. Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings. AIDS. 2014 Mar 13; 28(5):717-25.
    View in: PubMed
    Score: 0,094
  4. Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa. J Int AIDS Soc. 2013 Nov 19; 16:18794.
    View in: PubMed
    Score: 0,092
  5. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis. 2012 Jun; 54(11):1660-9.
    View in: PubMed
    Score: 0,082
  6. Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa. J Infect Dis. 2012 Jun; 205(11):1739-44.
    View in: PubMed
    Score: 0,082
  7. High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010 Apr 01; 53(4):500-6.
    View in: PubMed
    Score: 0,072
  8. Effect of pulmonary tuberculosis on mortality in patients receiving HAART. AIDS. 2009 Mar 27; 23(6):707-15.
    View in: PubMed
    Score: 0,067
  9. Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South Africa. AIDS Res Ther. 2018 04 10; 15(1):10.
    View in: PubMed
    Score: 0,031
  10. Marginal Structural Models to Assess Delays in Second-Line HIV Treatment Initiation in South Africa. PLoS One. 2016; 11(8):e0161469.
    View in: PubMed
    Score: 0,028
  11. Predictors and outcomes of Mycobacterium tuberculosis bacteremia among patients with HIV and tuberculosis co-infection enrolled in the ACTG A5221 STRIDE study. BMC Infect Dis. 2015 Jan 13; 15:12.
    View in: PubMed
    Score: 0,025
  12. HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes. J Acquir Immune Defic Syndr. 2013 Oct 01; 64(2):174-82.
    View in: PubMed
    Score: 0,023
  13. The early effects of stavudine compared with tenofovir on adipocyte gene expression, mitochondrial DNA copy number and metabolic parameters in South African HIV-infected patients: a randomized trial. HIV Med. 2013 Apr; 14(4):217-25.
    View in: PubMed
    Score: 0,021
  14. Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy. Antivir Ther. 2012; 17(2):313-20.
    View in: PubMed
    Score: 0,020
  15. Natural killer cell activation distinguishes Mycobacterium tuberculosis-mediated immune reconstitution syndrome from chronic HIV and HIV/MTB coinfection. J Acquir Immune Defic Syndr. 2011 Nov 01; 58(3):309-18.
    View in: PubMed
    Score: 0,020
  16. Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa. AIDS. 2010 Aug 24; 24(13):2041-50.
    View in: PubMed
    Score: 0,018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.